Russia Races to Final COVID-19 Vaccine Trials, Aiming for Mass Rollout
Russia, one of the world's hardest-hit nations by the COVID-19 pandemic with over 770,000 cases, is racing to develop a vaccine. Speculation swirls about potential data theft from Western labs to hasten its creation.
Russia has completed phase I/II trials of its COVID-19 vaccine, using an adenovirus vector. It tested two versions, with the first group consisting of 18 volunteers and the second of 23. The country aims to produce up to 20 million doses domestically by year-end, with at least 5 countries interested in production.
Phase III trials, involving thousands of candidates, are set to begin in Russia and other nations like the UAE. These trials will assess significant side effects and mass inoculation prospects. Despite safety confirmation, the vaccine's public rollout is planned for next month, concurrent with trials.
Russia's COVID-19 vaccine development is progressing rapidly, with phase III trials imminent. While safety has been confirmed, the vaccine's widespread use will depend on successful large-scale testing.
Read also:
- Rise in Flu Cases: Timing and Reasons Explored by Medical Experts for Flu Vaccination
- Nursing Infants: Advantages, Factors to Ponder, Guidelines, Essential Gear
- Anticipated Increase in Uninsured Residents to Pose Challenge for Local Healthcare Infrastructure
- Accusations of poor care and supposedly poor hygienic standards at LaSalle Hospital
